BOLT · Bolt Biotherapeutics, Inc.
$3.45
-0.06 (-1.71%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company believes that this raises substantial doubt about its ability to continue as a going concern within one year after the issuance of the unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 11, 2026
Market Cap
$6.93M
Shares
1.93M
Volume · Oct 2
885
Avg daily vol (3M)
25.46K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.45
Open$3.50
Day$3.45–3.50
52W close$3.18–7.09
Avg vol 30d31K
Short int18K · 1.0% float · 1.0d
Short vol53%
Last earningsAug 14, 2025
DataFeb 2021–Oct 2026
Filing10-Q · Aug 11
Up next
filed Aug 11, 2026
call held Mar 31, 2024
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$4.70M
Trailing 12 months
Net income (TTM)
−$28.74M
Trailing 12 months
Revenue growth YoY
-99.7%
Year over year
Operating margin
-654.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$17.60M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-11.8%
Year over year · fewer shares
Price change (1Y)
-30.4%
Trailing year
Short interest
1.0%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−25%
below
Price vs 50-day avg
−7%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
7%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−11%
trailing
6-month return
−26%
trailing
YTD return
−37%
this year
Relative strength
−38%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Distributing
-4% holders QoQ · +2 funds added
Insider flow
Distributing
Net -$128.3K over 90 days · 100% sells
Short interest
Rising
0.96% of float · ▲ +18.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
23 holders — mid 1-yr range
Squeeze score
43
elevated · 0–100
Fundamentals
Revenue growth
+0%
Y/Y
EPS growth
+46%
Y/Y
Free cash flow
$-39.9M
Quant / Vol
risk profile
Volatility
75%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
8.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−25%
Bearish
Price vs 50-day avg
−7%
Bearish
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
7%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Distributing
-4% holders QoQ · +2 funds added
Insider flow
Distributing
Net -$128.3K over 90 days · 100% sells
Short interest
Rising
0.96% of float · ▲ +18.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
23 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $3
Now $3 · 7%
Range high $7
vs 200-day avg -25%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BOLT
this stock
Bolt Biotherapeutics, Inc.
|
$6.93M | -36.9% | +0.1% | — | 1.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BOLT | -3.6% | -11.4% | -26.0% | -6.3% | -36.9% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -3.4% | -11.0% | -38.2% | -7.2% | -49.8% |